| Concord Biotech Limited | |
|---|---|
| Country: | India |
| Tel: | 91-2714-398200 |
| Mobile: | 91-2714-398200 |
| E-mail: | concord@concordbiotech.com |
| WhatsApp: | Chat Now! |
| Skype: | Chat Now! |
ABOUT US
Concord Biotech Limited is a R&D driven biopharma Company that manufactures Active Pharmaceutical Ingredients (API) through fermentation & semi-synthetic process and finished formulations. Concord, founded in the year 2000 has transformed from a single-product company to a broad-spectrum solution provider, offering products across diversified therapeutic segments.
Concord is globally known for its products and has a presence in more than 70 countries worldwide with efficient distribution infrastructure in markets like the USA, Europe, Japan, Latin America, Africa, Asia, besides significant presence in Indian market. Concord is actively expanding its horizons by partnering with leading global pharmaceutical companies by meeting their product development needs for APIs & finished formulations.
[About Us 05]
[About Us 05]
[About Us 05]
[About Us 05]
[About Us 05]
Concord has world-class manufacturing infrastructure. The Company has two API manufacturing units and one finished formulation unit, all located near Ahmedabad, Gujarat, India
Unit I (Dholka): Established in 2000, the Dholka facility is our first manufacturing facility for manufacturing APIs. Spread across an area of 112,302 sq.m., it comprises 22 manufacturing blocks that manufacture different classes of APIs. We manufacture all types of APIs in our product portfolio in Dholka facility. In 2005, it received its first USFDA inspection. It received inspections from USFDA, inspections from Government of Upper Bavaria for EUGMP certification, inspection from PMDA of Japan and inspection from MFDS of Korea.
Unit II (Valthera): The Valthera facility is formulation manufacturing facility that we established when we forayed into the formulation business in 2016. Spread across 94,826 sq.m., it currently contains manufacturing unit for oral solids, including tablets and capsules, and oral liquids, including oral solutions and oral suspensions. We are in the process of developing a liquid and lyophilized vials injectable line, a dry powder injectable line and a sterile powder bulk lyophilization line, which will be dedicated to manufacturing of injectables, including injectable liquids, lyophilized injectables and dry powder injectables, upon its completion. In the future, we aim to develop specialty formulations. The Valthera facility has received inspections from USFDA and inspection from WHO for GMP.